iRhythm Technologies Inc (IRTC) Cotización

Zio Services’ Clinically Proven Performance

The value of the Zio service has been demonstrated in over 100 original scientific research manuscripts5. Zio AT’s patient-centered design enables high patient compliance and analyzable time with minimal noise or artifact6-8, and real-world data shows an impressive 98% patient compliance9, in part thanks to Zio AT’s zero required patient manipulations. Furthermore, physicians agree with the Zio service's comprehensive end-of-wear report 99% of the time10-11.

About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all. To learn more about iRhythm, including its portfolio of Zio products and services, please visit irhythmtech.com.

Zio AT Indications For Use

The Zio AT device is intended to capture and transmit symptomatic and asymptomatic cardiac events and record continuous electrocardiogram (ECG) data for long-term monitoring. It is indicated for use on patients 18 years or older who may be asymptomatic or who may suffer from transient symptoms such as palpitations, shortness of breath, dizziness, light-headedness, pre-syncope, syncope, fatigue, or anxiety. It is not intended for use on critical care patients.

Grabar Law Office is investigating whether the Board of Directors of iRhythm Technologies, Inc. (NASDAQ: IRTC) ("iRhythm") breached their fiduciary duties to shareholders.

If you have held iRhythm shares since prior to January 11, 2022, learn more at https://grabarlaw.com/the-latest/irhythm-shareholder-investigation/, or call Joshua H. Grabar at 267-507-6085.

Earnings today AH …

$IRTC has $122.47M in debt

127.61 > hod.

iRhythm shares are trading higher following the release of the 2022 Medicare Physician Fee Schedule Final Rule by the Centers for Medicare and Medicaid Services.

iRhythm Technologies, Inc. is a digital healthcare company. It focuses on diagnosing cardiac arrhythmias by combining its wearable biosensing technology with cloud-based data analytics. It provides ambulatory electrocardiogram (ECG) monitoring for patients at risk for arrhythmias. It has created a portfolio of ambulatory cardiac monitoring services on a platform, called the Zio service. Its Zio service consists of wearable patch-based biosensors, Zio XT and Zio AT monitors, which records and stores ECG data from every patient heartbeat for up to 14 consecutive days. Zio service then provides cloud-based analysis of the recorded cardiac rhythms using its algorithms, an assessment review of the data by its cardiographic technicians, a report called Zio report, which includes the summary of findings and finally its cloud-based digital information system, ZioSuite, allows clinicians to connect via a Web browser or mobile application for online report interpretation and clinical workflows.